Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Achieve Life Sciences, Inc. stock logo
ACHV
Achieve Life Sciences
$2.37
+4.9%
$3.01
$1.84
$5.31
$78.39M1.51273,455 shs764,621 shs
Emergent Biosolutions Inc. stock logo
EBS
Emergent Biosolutions
$7.27
+5.8%
$6.30
$4.02
$15.10
$372.89M2.091.72 million shs1.78 million shs
Vanda Pharmaceuticals Inc. stock logo
VNDA
Vanda Pharmaceuticals
$5.02
+3.3%
$4.47
$3.81
$6.37
$286.42M0.68604,146 shs703,151 shs
Verastem, Inc. stock logo
VSTM
Verastem
$4.81
+2.1%
$6.27
$2.10
$9.10
$258.81M0.711.28 million shs1.97 million shs
The Best High-Yield Dividend Stocks for 2025 Cover

Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Achieve Life Sciences, Inc. stock logo
ACHV
Achieve Life Sciences
+9.18%+1.80%-40.99%+5.61%-50.66%
Emergent Biosolutions Inc. stock logo
EBS
Emergent Biosolutions
+3.77%+4.40%+3.61%+47.01%-15.48%
Vanda Pharmaceuticals Inc. stock logo
VNDA
Vanda Pharmaceuticals
-0.61%+3.85%+5.42%+17.68%-7.78%
Verastem, Inc. stock logo
VSTM
Verastem
+0.43%+9.79%-26.64%-10.80%+80.46%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Achieve Life Sciences, Inc. stock logo
ACHV
Achieve Life Sciences
1.6381 of 5 stars
3.80.00.00.02.50.00.6
Emergent Biosolutions Inc. stock logo
EBS
Emergent Biosolutions
4.1923 of 5 stars
3.51.00.04.61.42.51.3
Vanda Pharmaceuticals Inc. stock logo
VNDA
Vanda Pharmaceuticals
4.3803 of 5 stars
3.82.00.04.20.63.31.3
Verastem, Inc. stock logo
VSTM
Verastem
2.5594 of 5 stars
3.53.00.00.00.72.50.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Achieve Life Sciences, Inc. stock logo
ACHV
Achieve Life Sciences
3.50
Strong Buy$14.33504.78% Upside
Emergent Biosolutions Inc. stock logo
EBS
Emergent Biosolutions
3.00
Buy$14.3397.16% Upside
Vanda Pharmaceuticals Inc. stock logo
VNDA
Vanda Pharmaceuticals
3.50
Strong Buy$16.50228.69% Upside
Verastem, Inc. stock logo
VSTM
Verastem
3.00
Buy$13.38178.07% Upside

Current Analyst Ratings Breakdown

Latest ACHV, VNDA, EBS, and VSTM Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
6/25/2025
Verastem, Inc. stock logo
VSTM
Verastem
Royal Bank Of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeOutperform ➝ Moderate Buy$16.00 ➝ $12.00
5/14/2025
Vanda Pharmaceuticals Inc. stock logo
VNDA
Vanda Pharmaceuticals
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight$13.00
5/13/2025
Vanda Pharmaceuticals Inc. stock logo
VNDA
Vanda Pharmaceuticals
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeStrong-Buy
5/9/2025
Verastem, Inc. stock logo
VSTM
Verastem
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$10.00 ➝ $14.00
5/7/2025
Vanda Pharmaceuticals Inc. stock logo
VNDA
Vanda Pharmaceuticals
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$20.00 ➝ $20.00
4/10/2025
Verastem, Inc. stock logo
VSTM
Verastem
Jefferies Financial Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$15.00
4/9/2025
Verastem, Inc. stock logo
VSTM
Verastem
Mizuho
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOutperform ➝ Outperform$9.00 ➝ $8.00
(Data available from 7/9/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Achieve Life Sciences, Inc. stock logo
ACHV
Achieve Life Sciences
N/AN/AN/AN/A$0.61 per shareN/A
Emergent Biosolutions Inc. stock logo
EBS
Emergent Biosolutions
$1.04B0.38$2.03 per share3.58$8.91 per share0.82
Vanda Pharmaceuticals Inc. stock logo
VNDA
Vanda Pharmaceuticals
$198.77M1.49N/AN/A$9.24 per share0.54
Verastem, Inc. stock logo
VSTM
Verastem
$10K26,430.95N/AN/A($0.65) per share-7.40
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Achieve Life Sciences, Inc. stock logo
ACHV
Achieve Life Sciences
-$39.83M-$1.34N/AN/AN/AN/A-176.11%-103.32%8/12/2025 (Estimated)
Emergent Biosolutions Inc. stock logo
EBS
Emergent Biosolutions
-$190.60M-$2.71N/A3.51N/A-13.63%-0.52%-0.17%8/5/2025 (Estimated)
Vanda Pharmaceuticals Inc. stock logo
VNDA
Vanda Pharmaceuticals
-$18.90M-$0.75N/AN/AN/A-21.98%-8.30%-6.85%7/30/2025 (Estimated)
Verastem, Inc. stock logo
VSTM
Verastem
-$130.64M-$3.20N/AN/AN/AN/A-2,003.62%-127.97%8/6/2025 (Estimated)

Latest ACHV, VNDA, EBS, and VSTM Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/5/2025Q2 2025
Emergent Biosolutions Inc. stock logo
EBS
Emergent Biosolutions
$0.21N/AN/AN/A$148.55 millionN/A
7/30/2025Q2 2025
Vanda Pharmaceuticals Inc. stock logo
VNDA
Vanda Pharmaceuticals
-$0.34N/AN/AN/A$54.77 millionN/A
5/13/2025Q1 2025
Achieve Life Sciences, Inc. stock logo
ACHV
Achieve Life Sciences
-$0.37-$0.37N/A-$0.37N/AN/A
5/13/2025Q1 2025
Verastem, Inc. stock logo
VSTM
Verastem
-$0.72-$0.96-$0.24-$0.96$0.10 millionN/A
5/7/2025Q1 2025
Emergent Biosolutions Inc. stock logo
EBS
Emergent Biosolutions
$0.49$0.71+$0.22$1.19$218.50 million$222.20 million
5/7/2025Q1 2025
Vanda Pharmaceuticals Inc. stock logo
VNDA
Vanda Pharmaceuticals
-$0.55-$0.50+$0.05-$0.50$45.13 million$50.04 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Achieve Life Sciences, Inc. stock logo
ACHV
Achieve Life Sciences
N/AN/AN/AN/AN/A
Emergent Biosolutions Inc. stock logo
EBS
Emergent Biosolutions
N/AN/AN/AN/AN/A
Vanda Pharmaceuticals Inc. stock logo
VNDA
Vanda Pharmaceuticals
N/AN/AN/AN/AN/A
Verastem, Inc. stock logo
VSTM
Verastem
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Achieve Life Sciences, Inc. stock logo
ACHV
Achieve Life Sciences
0.85
3.51
3.51
Emergent Biosolutions Inc. stock logo
EBS
Emergent Biosolutions
1.20
6.32
3.51
Vanda Pharmaceuticals Inc. stock logo
VNDA
Vanda Pharmaceuticals
N/A
3.93
3.91
Verastem, Inc. stock logo
VSTM
Verastem
N/A
3.50
3.50

Institutional Ownership

CompanyInstitutional Ownership
Achieve Life Sciences, Inc. stock logo
ACHV
Achieve Life Sciences
33.52%
Emergent Biosolutions Inc. stock logo
EBS
Emergent Biosolutions
78.40%
Vanda Pharmaceuticals Inc. stock logo
VNDA
Vanda Pharmaceuticals
88.14%
Verastem, Inc. stock logo
VSTM
Verastem
88.37%

Insider Ownership

CompanyInsider Ownership
Achieve Life Sciences, Inc. stock logo
ACHV
Achieve Life Sciences
3.00%
Emergent Biosolutions Inc. stock logo
EBS
Emergent Biosolutions
1.20%
Vanda Pharmaceuticals Inc. stock logo
VNDA
Vanda Pharmaceuticals
10.00%
Verastem, Inc. stock logo
VSTM
Verastem
2.10%
CompanyEmployeesShares OutstandingFree FloatOptionable
Achieve Life Sciences, Inc. stock logo
ACHV
Achieve Life Sciences
2034.69 million33.64 millionOptionable
Emergent Biosolutions Inc. stock logo
EBS
Emergent Biosolutions
2,42054.28 million53.63 millionOptionable
Vanda Pharmaceuticals Inc. stock logo
VNDA
Vanda Pharmaceuticals
29058.93 million53.04 millionOptionable
Verastem, Inc. stock logo
VSTM
Verastem
5054.95 million53.80 millionOptionable

Recent News About These Companies

Verastem, Inc. (VSTM) - Yahoo Finance
BTIG Remains a Buy on Verastem (VSTM)

New MarketBeat Followers Over Time

Media Sentiment Over Time

Achieve Life Sciences stock logo

Achieve Life Sciences NASDAQ:ACHV

$2.37 +0.11 (+4.87%)
Closing price 04:00 PM Eastern
Extended Trading
$2.35 -0.02 (-0.84%)
As of 07:45 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Achieve Life Sciences, Inc., a clinical-stage pharmaceutical company, develops and commercializes cytisinicline for smoking cessation and nicotine addiction. The company offers cytisinicline, a plant-based alkaloid that interacts with nicotine receptors in the brain that reduce the severity of nicotine withdrawal symptoms. It has license and supply agreement with Sopharma AD and University of Bristol Achieve Life Sciences, Inc. is based in Vancouver, Canada.

Emergent Biosolutions stock logo

Emergent Biosolutions NYSE:EBS

$7.27 +0.40 (+5.82%)
Closing price 03:57 PM Eastern
Extended Trading
$7.34 +0.08 (+1.03%)
As of 07:57 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Emergent BioSolutions Inc., a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States. The company offers NARCAN Nasal Spray for the emergency treatment of known or suspected opioid overdose; Vaxchora vaccine for the prevention of cholera; Vivotif vaccine for oral administration for the prevention of typhoid fever; Anthrasil for the treatment of inhalational anthrax; BioThrax, an anthrax vaccine; CYFENDUS for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis; and Raxibacumab injection for the treatment and prophylaxis of inhalational anthrax. It also provides ACAM2000, a smallpox vaccine; CNJ-016 to address complications from smallpox vaccination; TEMBEXA for the treatment of smallpox disease caused by variola virus in adult and pediatric patients; BAT for the treatment of symptomatic botulism; Ebanga for the treatment of Ebola; Reactive Skin Decontamination Lotion Kit to remove or neutralize chemical warfare agents from the skin; Trobigard, a atropine sulfate obidoxime chloride auto-injector. In addition, the company is developing CGRD-001 for the treatment of poisoning by organophosphorus nerve agents or organophosphorus compounds; EBS-LASV to prevent Lassa fever; EBS-MARV to prevent Marburg virus disease; EBS-SUDV to prevent Sudan virus disease; Pan-Ebola mAbs for the treatment of ebola virus; SIAN Antidote for initial treatment of certain or suspected acute cyanide poisoning; UniFlu for immunity against influenza A and B viruses; and WEVEE-VLP for equine encephalitis virus infections. Further, it provides contract development and manufacturing services comprising drug substance and product manufacturing, and packaging, as well as technology transfer, process, and analytical development services. The company was incorporated in 1998 and is headquartered in Gaithersburg, Maryland.

Vanda Pharmaceuticals stock logo

Vanda Pharmaceuticals NASDAQ:VNDA

$5.02 +0.16 (+3.29%)
Closing price 04:00 PM Eastern
Extended Trading
$5.08 +0.06 (+1.10%)
As of 07:50 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company's marketed products include HETLIOZ to treat non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia. Its pipeline products include HETLIOZ (tasimelteon) to treat jet lag disorder, insomnia, delayed sleep phase disorder, sleep disturbances in autism spectrum disorder, and pediatric Non-24; Fanapt (iloperidone) for the treatment of bipolar I disorder and Parkinson's disease psychosis, as well as a long acting injectable (LAI) formulation to treat schizophrenia; and Tradipitant (VLY-686), a small molecule neurokinin-1 receptor (NK-1R) antagonist to treat gastroparesis, motion sickness, atopic dermatitis, and COVID-19 pneumonia. The company's pipeline products also include VTR-297, a small molecule histone deacetylase inhibitor to treat hematologic malignancies and with potential use as a treatment for various oncology indications; VQW-765, a small molecule nicotinic acetylcholine receptor partial agonist to treat performance anxiety and psychiatric disorders; VHX-896, an active metabolite of iloperidone; and antisense oligonucleotide molecules. In addition, it offers a portfolio of cystic fibrosis transmembrane conductance regulator activators and inhibitors that include VSJ-110 for the treatment of dry eye and ocular inflammation; and VPO-227 for the treatment of secretory diarrhea disorders comprising cholera. Vanda Pharmaceuticals Inc. was incorporated in 2002 and is headquartered in Washington, the District of Columbia.

Verastem stock logo

Verastem NASDAQ:VSTM

$4.81 +0.10 (+2.12%)
Closing price 04:00 PM Eastern
Extended Trading
$4.81 0.00 (0.00%)
As of 07:58 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Verastem, Inc., a development-stage biopharmaceutical company, focuses on developing and commercializing drugs for the treatment of cancer in the United States. Its product candidates are Avutometinib, an orally available small molecule RAF/MEK clamp that inhibits the ras sarcoma RAF/MEK, ERK mitogen activated pathway kinase pathway which is involved in cell proliferation, migration, transformation, and survival of tumor cells; and Defactinib, an oral small molecule inhibitor of FAK and proline-rich tyrosine kinase for various solid tumors. The company is involved in clinical studies, including RAMP 301, a randomized global confirmatory trial to evaluate the combination of Avutometinib and Defactinib for the treatment of patients with recurrent low-grade serous ovarian cancer; RAMP 201, an adaptive two-part multicenter, parallel cohort, randomized open label trial to evaluate the efficacy and safety of Avutometinib and in combination with Defactinib; and FRAME, an investigation of Avutometinib and Defactinib in patients with KRAS mutant cancers and subsequent analyses; and RAMP 204 and 205. It has license agreements with Chugai Pharmaceutical Co., Ltd. for the development, commercialization, and manufacture of products containing Avutometinib; and Pfizer Inc. to research, develop, manufacture, and commercialize products containing Pfizer's inhibitors of FAK for therapeutic, diagnostic, and prophylactic uses in humans. In addition, it has a clinical collaboration agreement with Amgen, Inc. to evaluate the combination of Avutometinib with Amgen's KRAS-G12C inhibitor LUMAKRAS which in Phase 1/2 trial entitled RAMP 203; and a discovery and development collaboration with GenFleet Therapeutics to advance new programs targeting RAS pathway-driven cancers. Verastem, Inc. was incorporated in 2010 and is headquartered in Needham, Massachusetts.